Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-11. (Canceled)

12. (Currently amended): A synthesized peptide comprising one or more sequences selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8 ~~and SEQ ID NO:11~~.

13. (Original): An osteogenetic accelerator comprising the peptide set forth in claim 12, or a pharmacologically acceptable salt thereof, attached to a biocompatible carrier.

14. (Original): An osteogenetic accelerator comprising the peptide of claim 12, or a pharmacologically acceptable salt thereof, mixed with, dissolved in, or suspended in aqueous solvent.

15. (Currently amended): A synthesized peptide comprising the sequence SEQ ID NO:11, wherein the peptide N-terminal is acetylated, or the peptide C-terminal is amidated, or both the N-terminal is acetylated and the C-terminal is amidated.

16. (Previously presented): An osteogenetic accelerator comprising the peptide set forth in claim 15, or a pharmacologically acceptable salt thereof, attached to a biocompatible carrier.

17. (Previously presented): The osteogenetic accelerator according to claim 16, wherein the carrier is selected from a group consisting of a ceramic, an artificial bone, a covalently cross-linked gel of alginate, and a gel of collagen, hyaluronic acid, calcium sulfate, polylactic acid, polyglycolic acid, hydroxyapatite, tricalcium phosphate, starch, chitin/chitosan, agarose, or dextran.

18 (Previously presented): The osteogenetic accelerator according to claim 16 which contains 0.01 to 50 parts by weight of the peptide per 100 parts by weight of the carrier.

19. (Previously presented): An osteogenetic accelerator comprising the peptide of claim 15, or a pharmacologically acceptable salt thereof, mixed with, dissolved in, or suspended in aqueous solvent.

20. (Previously presented): The osteogenetic accelerator according to claim 19, wherein the aqueous solvent is physiological saline solution or a physiologically acceptable aqueous solution selected from a group consisting of mannitol, sucrose, lactose, maltose, glucose, and fructose.

21. (Previously presented): The osteogenetic accelerator according to claim 19 or 20, wherein the concentration of the peptide is 0.001% to 5% with respect to the aqueous solvent.

22. (Previously presented): The osteogenetic accelerator as set forth in claim 16 which is used for treating a bone fracture by inducing bone formation at the fracture site or for inhibiting a decrease in bone substance.

23. (Canceled)

24. (Previously presented): An osteogenetic accelerator comprising a physiologically acceptable salt of the peptide set forth in claim 15.

25. (New): A synthesized peptide consisting essentially of the sequence SEQ ID NO:11.

26. (New): An osteogenetic accelerator comprising the peptide set forth in claim 25, or a pharmacologically acceptable salt thereof, attached to a biocompatible carrier.

27. (New): The osteogenetic accelerator according to claim 26, wherein the carrier is selected from a group consisting of a ceramic, an artificial bone, a covalently cross-linked gel of alginate, and a gel of collagen, hyaluronic acid, calcium sulfate, polylactic acid, polyglycolic acid, hydroxyapatite, tricalcium phosphate, starch, chitin/chitosan, agarose, or dextran.

28 (New): The osteogenetic accelerator according to claim 26 which contains 0.01 to 50 parts by weight of the peptide per 100 parts by weight of the carrier.

29. (New): An osteogenetic accelerator comprising the peptide of claim 25, or a pharmacologically acceptable salt thereof, mixed with, dissolved in, or suspended in aqueous solvent.

30. (New): The osteogenetic accelerator according to claim 29, wherein the aqueous solvent is physiological saline solution or a physiologically acceptable aqueous solution selected from a group consisting of mannitol, sucrose, lactose, maltose, glucose, and fructose.

31. (New): The osteogenetic accelerator according to claim 29 or 30, wherein the concentration of the peptide is 0.001% to 5% with respect to the aqueous solvent.

32. (New): The osteogenetic accelerator as set forth in claim 26 which is used for treating a bone fracture by inducing bone formation at the fracture site or for inhibiting a decrease in bone substance.

33. (New): The peptide of claim 25, wherein the peptide N-terminal is acetylated, or the peptide C-terminal is amidated, or both the N-terminal is acetylated and the C-terminal is amidated.

34. (New): An osteogenetic accelerator comprising a physiologically acceptable salt of the peptide set forth in claim 25.

35. (New): A synthesized peptide consisting of the sequence SEQ ID NO:11.